| 13.17 Data as of May 24 |  +0.46 / +3.62%Today’s Change | 6.25 Today|||52-Week Range 13.23 | +76.07% Year-to-Date |
| Commit To Buy Neurocrine Biosciences At $9, Earn 28.8% Annualized May 24 / TheStreet.com |
| Previous close | 12.71 |
| Today’s open | 12.63 |
| Day’s range | 12.62 - 13.23 |
| Volume | 592,899 |
| Average volume (3 months) | 511,375 |
| Market cap | $878.9M |
| Dividend yield | -- |
| Earnings growth (last year) | -88.06% |
| Earnings growth (this year) | -1,098.44% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -31.36% |
| P/E ratio | NM |
| Price/Sales | 9.24 |
| Price/Book | 5.67 |
| Today’s change | Today’s % change | |
|---|---|---|
| USNAUSANA Health Science... | -1.18 | -1.72% |
| CLVSClovis Oncology Inc | +1.10 | +3.28% |
| AUXLAuxilium Pharmaceuti... | -0.08 | -0.52% |
| ACHNAchillion Pharmaceut... | -0.06 | -0.79% |
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | -$0.20 |
| Annual revenue (last year) | $53.1M |
| Annual profit (last year) | $5.0M |
| Net profit margin | 9.46% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Kevin C. Gorman, PhD, MBA |
Vice President-Information Technology & Operations Bill Wilson |
Corporate headquarters San Diego, California |
.
